Chronic Myelod Leukemia Registry at Asan Medical Center

NCT01761695 | Terminated

• 1 other identifier: AMC-HEMREG-CML
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The investigators would like to propose a prospective longitudinal observational cohort study for patients who will be diagnosed and/or treated for chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, to use the acquired data for fundamentals of other retrospective analysis.

Conditions

Leukemia, Chronic Myeloid; Myeloid Leukemia, Chronic, Accelerated Phase; Myeloid Leukemia, Chronic, Chronic Phase

Outcome Measures

Primary Outcomes (1)

• Overall survival

  30 years

Secondary Outcomes (2)

• Event-free survival

  30 years

• Failure-free survival

  30 years

Study Arms (4)

CML CP

Diagnosed as CML with chronic phase

Other: Diagnosed as CML

CML AP

Diagnosed as CML with accelerated phase

Other: Diagnosed as CML

CML BC

Diagnosed as CML with blast crisis

Other: Diagnosed as CML

CML other

Diagnosed as CML, which is not included in any of other category

Other: Diagnosed as CML

Interventions

Diagnosed as CML OTHER

All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047

Also known as: Diagnosed as chronic myeloid leukemia

CML AP; CML BC; CML CP; CML other

Eligibility Criteria

• Age: 15 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who are diagnosed and/or treated with chronic myeloid leukemia at Asan Medical Center, Seoul, Korea

You may qualify if:

• All patients who are diagnosed and/or treated as chronic myeloid leukemia at Asan Medical Center
• years of age and over
• All patients who give written consent according to guidelines at Asan Medical Center committee on human research

You may not qualify if:

• Patients who refuse to give consent to registering

Sponsors & Collaborators

• Asan Medical Center: lead

Study Sites (1)

Asan Medical Center

Seoul, 138-736, South Korea

Location

Biospecimen

Retention: SAMPLES WITH DNA

Bone marrow aspirate or peripheral blood (for its mononuclear cells) will be collected, processed, and cryopreserved for future analysis of DNA or cell culture. Acquisition of biospecimens will be proceeded if patient agree with the informed consent for donation of biospecimen to 'Asan Medical Center Biomaterial Resource Banking Center'. This registry data will be used as a basic demographic and clinical information for the biospecimens.

MeSH Terms

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Myeloproliferative Disorders; Bone Marrow Diseases; Hematologic Diseases; Hemic and Lymphatic Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Dae-Young Kim, MD

  Assistant Professor

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 30 Years
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor

Study Record Dates

• First Submitted: January 3, 2013
• First Posted: January 7, 2013
• Study Start: January 1, 2013
• Primary Completion: May 1, 2016
• Study Completion: May 1, 2016
• Last Updated: July 20, 2018

Record last verified: 2018-07

Locations

KR (1)